DMSO and Cataract Risk
The FDA drug label for topical dimethyl sulfoxide (RIMSO-50®) explicitly warns that lens changes and opacities have been observed in animals given high doses chronically, and therefore recommends full eye evaluations including slit lamp examinations prior to treatment and approximately every six months during therapy. 1
Evidence from FDA Drug Labeling
The most authoritative source on this topic is the FDA-approved drug label for DMSO, which states:
- Lens opacities and changes in refractive index were documented in monkeys, dogs, and rabbits receiving chronic high-dose DMSO 1
- Mandatory ophthalmologic monitoring is required: Full eye evaluations with slit lamp examinations should be performed before initiating DMSO and approximately every 6 months during treatment 1
- This precaution applies specifically to systemic or high-dose chronic exposure, as the animal studies used high doses over extended periods 1
Clinical Context and Risk Stratification
The cataract risk from DMSO must be understood in context:
- Animal studies used substantially higher doses than typical human therapeutic applications 1
- The FDA warning is based on chronic high-dose exposure in animal models, not on documented human cataract cases from therapeutic DMSO use 1
- Human clinical experience suggests DMSO exhibits "low to none observed ocular or systemic ocular toxicity" when used appropriately 2
Practical Clinical Implications
For patients using DMSO topically for musculoskeletal pain or diabetic neuropathy:
- The risk appears dose-dependent: Higher concentrations and chronic use carry greater theoretical risk based on animal data 1
- Topical application for pain relief typically involves lower systemic absorption than the routes used in animal toxicity studies 3
- Most adverse reactions to DMSO in humans are transient, mild, and primarily gastrointestinal or dermatologic rather than ophthalmologic 4
Monitoring Recommendations
Based on FDA labeling, any patient receiving chronic DMSO therapy should undergo:
- Baseline comprehensive eye examination with slit lamp evaluation before starting treatment 1
- Follow-up ophthalmologic examinations every 6 months during ongoing therapy 1
- Biochemical screening (liver and renal function, complete blood count) every 6 months 1
Important Caveats
- The established medication-related cataract risks involve corticosteroids (oral or inhaled), not DMSO 5, 6
- No human studies in the provided evidence document actual cataract formation from therapeutic DMSO use for pain conditions 2, 4
- The FDA precaution is appropriately conservative given animal data, but represents theoretical rather than clinically documented human risk 1